Integra Holdings

Integra Holdings represents a distinctive investment vehicle that seamlessly integrates academic innovation with commercial expertise. Established by Yissum, the technology transfer arm of the Hebrew University of Jerusalem, this venture fund specializes in transforming cutting-edge research into marketable solutions. The fund's strategic advantage lies in its direct access to the continuous flow of groundbreaking applied research emerging from one of Israel's most prestigious academic institutions. This privileged position allows Integra to identify and nurture promising biotech innovations at their earliest stages.

With a highly selective investment approach, Integra focuses exclusively on biotech companies demonstrating proprietary technologies and clear competitive advantages in their respective markets. The fund distinguishes itself through its hands-on management style, providing portfolio companies with comprehensive strategic planning and business development resources. This active involvement extends beyond mere financial backing, encompassing crucial guidance through regulatory pathways, clinical development strategies, and market entry planning—elements particularly vital in the complex biotech sector.

Integra's investor base reflects its strong market position and credibility, comprising notable institutions including Temasek, Arie Capital, Invatech Holdings, Halman-Aldubi Provident and Pension Fund, HUJI Fund, and the Israeli Teachers Fund. The fund's inaugural investment round was successfully led by Invatech, representing a consortium of private investors from both the United States and Israel. This diverse financial backing provides Integra with substantial capital resources and an extended network of industry connections across multiple markets and territories.

Leveraging nearly five decades of accumulated business expertise, Integra has developed extensive global networks that significantly enhance its commercialization capabilities. The fund typically engages with early to mid-stage ventures, providing not only capital but also critical expertise in intellectual property protection, regulatory navigation, and market positioning. This comprehensive approach has positioned Integra as a valuable bridge between academic innovation and commercial success, particularly in therapeutic areas, medical devices, and diagnostic technologies where the path from laboratory to market presents numerous complex challenges.